CYTOMEGALOVIRUS COLITIS POST IL-6 INHIBITOR USE IN COVID-19 INFECTION

被引：4
|
作者：
Jiwa, Nasheena
Lorick, Kiran
Mutneja, Rahul
机构：
来源：
CHEST | 2020年 / 158卷 / 04期
关键词：
D O I：
10.1016/j.chest.2020.08.719
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：772A / 772A
页数：1
相关论文
共 50 条
  • [41] Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19
    Khaedir, Yordan
    Kartika, Rona
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2021, 41 (02): : 37 - 43
  • [42] IL-6 modulation for COVID-19: the right patients at the right time?
    Ascierto, Paolo Antonio
    Fu, Binqing
    Wei, Haiming
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (04)
  • [43] Multimodality treatment in immunocompromised patients with severe COVID-19: the role of IL-6 inhibitor, intravenous immunoglobulin, and haemoperfusion
    Leelayuwatanakul, Nophol
    Kongpolprom, Napplika
    Sriprasart, Thitiwat
    Phoophiboon, Vorakamol
    Thanthitaweewat, Vorawut
    Thawanaphong, Sarita
    Sirichana, Worawan
    Chirakalwasan, Naricha
    Kawkitinarong, Kamon
    Sittipunt, Chanchai
    Putcharoen, Opass
    Paitoonpong, Leilani
    Suwanpimolkul, Gompol
    Jantarabenjakul, Watsamon
    Srisawat, Nattachai
    Pachinburavan, Monvasi
    RESPIROLOGY CASE REPORTS, 2021, 9 (04):
  • [44] Experience of anticipatory therapy with IL-6 receptor inhibitors and perspectives for its use in the evolution of COVID-19
    Chulanov, Vladimir P.
    Bakirov, Bulat A.
    Vezikova, Natalia N.
    Gorodin, Vladimir N.
    V. Zhuravleva, Marina
    Zagrebneva, Alena I.
    Ivanov, Igor G.
    V. Lomakin, Nikita
    V. Lukina, Galina
    Moysova, Diana L.
    Mutovina, Zinaida Iu.
    TERAPEVTICHESKII ARKHIV, 2022, 94 (08) : 1028 - 1035
  • [45] Interleukin-6 (IL-6) as a Predictor of Clinical Outcomes in Patients with COVID-19
    Mahmood, Saad B. Z.
    Majid, Hafsa
    Arshad, Ainan
    Zaib-Un-Nisa, Noureen
    Niazali, Noureen
    Kazi, Kulsum
    Aslam, Aashir
    Ahmed, Sibtain
    Jamil, Bushra
    Jafri, Lena
    CLINICAL LABORATORY, 2023, 69 (06) : 1126 - 1133
  • [46] Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together?
    A. Berni
    D. Malandrino
    G. Parenti
    M. Maggi
    L. Poggesi
    A. Peri
    Journal of Endocrinological Investigation, 2020, 43 : 1137 - 1139
  • [47] COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status
    Thomas, Tiffany
    Stefanoni, Davide
    Reisz, Julie A.
    Nemkov, Travis
    Bertolone, Lorenzo
    Francis, Richard O.
    Hudson, Krystalyn E.
    Zimring, James C.
    Hansen, Kirk C.
    Hod, Eldad A.
    Spitalnik, Steven L.
    D'Alessandro, Angelo
    JCI INSIGHT, 2020, 5 (14)
  • [48] The potential of COVID-19 patients’ sera to cause antibody-dependent enhancement of infection and IL-6 production
    Jun Shimizu
    Tadahiro Sasaki
    Atsushi Yamanaka
    Yoko Ichihara
    Ritsuko Koketsu
    Yoshihiro Samune
    Pedro Cruz
    Kei Sato
    Naomi Tanga
    Yuka Yoshimura
    Ami Murakami
    Misuzu Yamada
    Kiyoe Itoi
    Emi E. Nakayama
    Kazuo Miyazaki
    Tatsuo Shioda
    Scientific Reports, 11
  • [49] Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together?
    Berni, A.
    Malandrino, D.
    Parenti, G.
    Maggi, M.
    Poggesi, L.
    Peri, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2020, 43 (08) : 1137 - 1139
  • [50] IL-6 serum level, ARDS, and AKI as risk factors for the COVID-19 infection's mortality in children
    Ganda, Idham Jaya
    Putri, Try Kartika Eka
    Rauf, Syarifuddin
    Laompo, Amiruddin
    Pelupessy, Ninny Meutia
    Lawang, Sitti Aizah
    Ridha, Nadirah Rasyid
    Fikri, Bahrul
    Massi, Muhammad Nasrum
    PLOS ONE, 2023, 18 (10):
12345